Microfluidics for the detection of minimal residual disease in acute myeloid leukemia patients using circulating leukemic cells selected from blood.

We report a highly sensitive microfluidic assay to detect minimal residual disease (MRD) in patients with acute myeloid leukemia (AML) that samples peripheral blood to search for circulating leukemic cells (CLCs). Antibodies immobilized within three separate microfluidic devices affinity-selected CLC subpopulations directly from peripheral blood without requiring pre-processing. The microfluidic devices targeted CD33, CD34, and CD117 cell surface antigens commonly expressed by AML leukemic cells so that each subpopulation's CLC numbers could be tracked to determine the onset of relapse. Staining against aberrant markers (e.g. CD7, CD56) identified low levels (11-2684 mL(-1)) of CLCs. The commonly used platforms for the detection of MRD for AML patients are multi-parameter flow cytometry (MFC), typically from highly invasive bone marrow biopsies, or PCR from blood samples, which is limited to <50% of AML patients. In contrast, the microfluidic assay is a highly sensitive blood test that permits frequent sampling for >90% of all AML patients using the markers selected for this study (selection markers CD33, CD34, CD117 and aberrant markers such as CD7 and CD56). We present data from AML patients after stem cell transplant (SCT) therapy using our assay. We observed high agreement of the microfluidic assay with therapeutic treatment and overall outcome. We could detect MRD at an earlier stage compared to both MFC and PCR directly from peripheral blood, obviating the need for a painful bone marrow biopsy. Using the microfluidic assay, we detected MRD 28 days following one patient's SCT and the onset of relapse at day 57, while PCR from a bone marrow biopsy did not detect MRD until day 85 for the same patient. Earlier detection of MRD in AML post-SCT enabled by peripheral blood sampling using the microfluidic assay we report herein can influence curative clinical decisions for AML patients.

[1]  K. Foon,et al.  Immunologic Approaches to the Classification and Management of Lymphomas and Leukemias , 2012, Cancer Treatment and Research.

[2]  Chronic Disease Division.  Cancer facts and figures , 2010 .

[3]  D. Grimwade,et al.  Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"? , 2014, Blood.

[4]  G. Lip,et al.  Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer. , 2006, Neoplasia.

[5]  L. Christophorou.  Science , 2018, Emerging Dynamics: Science, Energy, Society and Values.

[6]  H. Deeg,et al.  Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Steven A. Soper,et al.  Parallel Affinity-Based Isolation of Leukocyte Subsets Using Microfluidics: Application for Stroke Diagnosis , 2014, Analytical chemistry.

[8]  D. Hammer,et al.  The forward rate of binding of surface-tethered reactants: effect of relative motion between two surfaces. , 1999, Biophysical journal.

[9]  R. Hills,et al.  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. , 2010, Blood.

[10]  R. Wäsch,et al.  Evaluation of immunomodulatory treatment based on conventional and lineage-specific chimerism analysis in patients with myeloid malignancies after myeloablative allogeneic hematopoietic cell transplantation , 2005, Leukemia.

[11]  Keith Wheatley,et al.  Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial , 1998, The Lancet.

[12]  S. Soper,et al.  Arrays of high-aspect ratio microchannels for high-throughput isolation of circulating tumor cells (CTCs) , 2014, Microsystem technologies : sensors, actuators, systems integration.

[13]  Lishu Cao.  Int J Cancer：戒烟可以改善恶性肿瘤患者预后 , 2017 .

[14]  S. Soper,et al.  Enzymatic cleavage of uracil-containing single-stranded DNA linkers for the efficient release of affinity-selected circulating tumor cells. , 2015, Chemical communications.

[15]  T. Haferlach,et al.  Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. , 2009, Blood.

[16]  G. Schuurhuis,et al.  Minimal residual disease in acute myeloid leukemia: already predicting a safe haven? , 2010, Expert review of hematology.

[17]  S Chien,et al.  Morphometry of human leukocytes. , 1980, Blood.

[18]  L Davies,et al.  Bone marrow transplant. , 1985, Nursing times.

[19]  Paul I. Okagbare,et al.  Highly efficient circulating tumor cell isolation from whole blood and label-free enumeration using polymer-based microfluidics with an integrated conductivity sensor. , 2008, Journal of the American Chemical Society.

[20]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[21]  Albert D Donnenberg,et al.  Rare-event analysis in flow cytometry. , 2007, Clinics in laboratory medicine.

[22]  M. Labopin,et al.  Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Augustin Ferrant,et al.  Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? , 2007, Blood.

[24]  J. Dick,et al.  Characterization in vitro and engraftment potential in vivo of human progenitor T cells generated from hematopoietic stem cells. , 2009, Blood.

[25]  S. Soper,et al.  UV activation of polymeric high aspect ratio microstructures: ramifications in antibody surface loading for circulating tumor cell selection. , 2014, Lab on a chip.

[26]  R. Rosenfeld.  Nature , 2009, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[27]  Bob Löwenberg,et al.  Prognostic index for adult patients with acute myeloid leukemia in first relapse. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  François-Clément Bidard,et al.  High purity microfluidic sorting and analysis of circulating tumor cells: towards routine mutation detection. , 2015, Lab on a chip.

[29]  U. G. Dailey.  Cancer,Facts and Figures about. , 2022, Journal of the National Medical Association.

[30]  J. Dick,et al.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.

[31]  C. D. Wu,et al.  B-cell lymphomas with coexpression of CD5 and CD10. , 2003, American journal of clinical pathology.

[32]  G. I. Bell.  Models for the specific adhesion of cells to cells. , 1978, Science.

[33]  C. Bloomfield,et al.  High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). , 2001, Blood.

[34]  Leon W M M Terstappen,et al.  Statistical considerations for enumeration of circulating tumor cells , 2007, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[35]  Aaas News,et al.  Book Reviews , 1893, Buffalo Medical and Surgical Journal.

[36]  S. Schrier,et al.  Hematology-1993 : the education program of the American Society of Hematology , 1993 .

[37]  P. Sperryn,et al.  Blood. , 1989, British journal of sports medicine.

[38]  David Gillis,et al.  The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia. , 2009, American journal of clinical pathology.

[39]  J. Jorgensen,et al.  Multi-color flow cytometric immunophenotyping for detection of minimal residual disease in AML: past, present and future , 2014, Bone Marrow Transplantation.

[40]  S. Soper,et al.  Modular microsystem for the isolation, enumeration, and phenotyping of circulating tumor cells in patients with pancreatic cancer. , 2013, Analytical chemistry.

[41]  Joshua F. McMichael,et al.  Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing , 2011, Nature.

[42]  D. Steinbach,et al.  What do we mean by sensitivity when we talk about detecting minimal residual disease? , 2008, Leukemia.

[43]  Rajan P Kulkarni,et al.  Size-selective collection of circulating tumor cells using Vortex technology. , 2014, Lab on a chip.

[44]  Bart M. G. Smits,et al.  Effective flow cytometric phenotyping of cells using minimal amounts of antibody. , 2012, BioTechniques.

[45]  M. de Lima,et al.  Prevention and treatment of acute myeloid leukemia relapse after allogeneic stem cell transplantation , 2011, Current opinion in hematology.

[46]  J. Dongen,et al.  Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol , 2010, Leukemia.

[47]  B. Huntly,et al.  Recent advances in acute myeloid leukemia stem cell biology , 2012, Haematologica.

[48]  Jonathan W. Uhr,et al.  Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases , 2004, Clinical Cancer Research.

[49]  Steven A. Soper,et al.  Evaluation of micromilled metal mold masters for the replication of microchip electrophoresis devices , 2006 .

[50]  V. Diehl,et al.  Isolation of viable Hodgkin and Reed-Sternberg cells from Hodgkin disease tissues. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[51]  S. Soper,et al.  Sinusoidal Microchannels with High Aspect Ratios for CTC Selection and Analysis , 2016 .

[52]  S. Schnittger,et al.  Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. , 2011, Blood.

[53]  宁北芳,et al.  疟原虫var基因转换速率变化导致抗原变异[英]／Paul H, Robert P, Christodoulou Z, et al//Proc Natl Acad Sci U S A , 2005 .

[54]  S. Soper,et al.  Solid-phase extraction and purification of membrane proteins using a UV-modified PMMA microfluidic bioaffinity μSPE device. , 2014, The Analyst.